News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stealth Peptides Inc. Release: Researchers Present Promising Bendavia Findings at Annual Stealth Peptides Inc. Meeting


11/15/2011 7:16:21 AM

BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, reported today on Bendavia study findings presented during the annual American Society of Nephrology (ASN) meeting. Bendavia™ is a novel compound that targets the mitochondrion to treat mitochondrial dysfunction including ischemia reperfusion and microvascular injuries. ASN is a U.S. nonprofit organization that leads the fight against kidney disease by educating healthcare professionals and advancing basic and clinical research. ASN’s “Kidney Week 2011” meeting was held November 8th through November 13th in Philadelphia, where over 13,000 nephrology professionals gathered to exchange knowledge and learn the latest on scientific and medical advances.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES